Protalix BioTherapeutics, Inc.
Form 8-K November 30, 2016
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 30, 2016
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
- · · · · · · · · · · · · · · · · · · ·

Delaware (State or other jurisdiction of incorporation	001-33357 on) (Commission File Number	65-0643773 ) (IRS Employer Identification No.)
2 Snunit Street 20 Science Park, POB 455 Carmiel, Israel (Address of principal executive offices) (Z	ip Code)	
Registrant's telephone number, including	area code +972-4-988-9488	
(Former name or former address, if chang	ged since last report.)	
Check the appropriate box below if the Form the registrant under any of the following pro-	•	
"Written communications pursuant to Rule 4 "Soliciting material pursuant to Rule 14a-12 "Pre-commencement communications pursua "Pre-commencement communications pursua	under the Exchange Act (17 CF) ant to Rule 14d-2(b) under the E	R 240.14a-12) xchange Act (17 CFR 240.14d-2(b))

#### Item 8.01. Other Events

On November 30, 2016, Protalix BioTherapeutics, Inc. issued a press release announcing that the first patient has been enrolled in its phase II clinical trial of OPRX-106 for the treatment of ulcerative colitis. OPRX-106 is a plant cell-expressed recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain (TNFRII-Fc). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

#### Item 9.01. Financial Statements and Exhibits

## (d) Exhibits

99.1 Press release dated November 30, 2016.

Edgar Filing: Protalix BioTherapeutics, Inc. - Form 8-K

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

# PROTALIX BIOTHERAPEUTICS, INC.

Date: November 30, 2016 By: /s/ Moshe Manor

Name: Moshe Manor

Title: President and Chief Executive Officer